Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Public ClinicalTrials.gov record NCT00299494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin \[CMC-544\] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.
Study identification
- NCT ID
- NCT00299494
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 119 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 4, 2006 (Actual)
- Primary completion
- May 19, 2014 (Actual)
- Completion
- Jun 2, 2014 (Actual)
- Last update posted
- Mar 8, 2018
2006 – 2014
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham- | Birmingham | Alabama | 35249 - 3300 | — |
| IDS Pharmacy | Birmingham | Alabama | 35249 | — |
| University of Alabama at Birmingham- | Birmingham | Alabama | 35294 | — |
| California Cancer Care, Inc. | Greenbrae | California | 94904 | — |
| University of California Medical Center | San Francisco | California | 94143 | — |
| California Cancer Care | San Mateo | California | 94402 | — |
| Emory Clinic | Atlanta | Georgia | 30322 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Emory University Investigational Drug Service | Atlanta | Georgia | 30322 | — |
| Northwestern Medical Faculty Foundation | Chicago | Illinois | 60611 | — |
| Nevada Cancer Institute- | Las Vegas | Nevada | 89135 | — |
| Rosewell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Gabrail Cancer Center | Dover | Ohio | 44622 | — |
| UHHS - Westlake | Westlake | Ohio | 44145 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00299494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2018 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00299494 live on ClinicalTrials.gov.